Floatz logo

Thiotepa

Acute Leukemia

Sawa Ito, MDSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Acute Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 2/3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
Janssen Research & Development, LLC
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB
ETOPOSIDE
Nanfang Hospital, Southern Medical University
Phase 2/3BB

View all 50 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
juvenile myelomonocytic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →